AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38580133 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) for relative indication EGC
Number of subjects: 149
Study 38580298 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Number of subjects: 272
Study 38580298 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 272
Study 38580333 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoPET imaging with PD-L1-targeted tracers
Number of subjects: 0
Study 38580339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided high-intensity focused ultrasound (HIFU)
Number of subjects: 30
Study 38580350 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 793
Study 38580350 — intervention group
Group type: COMPARATOR
Intervention: Any treatment (conventional or biological antirheumatic treatment)
Number of subjects: 793
Study 38580355 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists (clonidine and dexmedetomidine)
Number of subjects: 39
Study 38580355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39
Study 38580363 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition with arginine-enhanced diets
Number of subjects: 45
Study 38580363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study 38580373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (pharmacological nutritional hypercaloric products)
Number of subjects: 0
Study 38580373 — intervention group
Group type: COMPARATOR
Intervention: Age-appropriate and gender-appropriate nutritional intake
Number of subjects: 0
Study 38580386 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg vedo-800CW
Number of subjects: 43
Study 38580386 — intervention group
Group type: COMPARATOR
Intervention: 15 mg vedo-800CW after unlabelled vedolizumab
Number of subjects: 43
Study 38580386 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg vedo-800CW
Number of subjects: 43
Study 38580424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4017
Study 38580424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4017
Study 38580444 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly emailed behavioural 'nudge' messages encouraging compliance with social norms and clinical guidelines around prescribing.
Number of subjects: 36
Study 38580558 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 283
Study 38580558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 283
Study 38580558 — intervention group
Group type: COMPARATOR
Intervention: Control (non-anticoagulated)
Number of subjects: 283
Study 38580913 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motor-cognitive eHealth exercise intervention using the ExorLive® application for 10 weeks
Number of subjects: 15
Study 38580946 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0
Study 38580946 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study 38580992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical Family Guidance (DFG)
Number of subjects: 50
Study 38580992 — intervention group
Group type: COMPARATOR
Intervention: Control group (DFG after a three-month waiting period)
Number of subjects: 50
Study 38581030 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile sedation
Number of subjects: 0
Study 38581030 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 0
Study 38581046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise
Number of subjects: 35
Study 38581046 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 35
Study 38581075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 194
Study 38581075 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 194
Study 38581075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) and procalcitonin (PCT)
Number of subjects: 194
Study 38581363 — intervention group
Group type: EXPERIMENTAL
Intervention: Work schedule with abated quick returns (i.e. > 11 hours between two shifts)
Number of subjects: 1314
Study 38581363 — intervention group
Group type: COMPARATOR
Intervention: Control group (shift schedule maintaining the usual number of quick returns)
Number of subjects: 1314
Study 38581389 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 6522
Study 38581389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study 38581449 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 (slow-twitch) fibres
Number of subjects: 18
Study 38581449 — intervention group
Group type: COMPARATOR
Intervention: Type 2 (fast-twitch) fibres
Number of subjects: 18
Study 38581469 — intervention group
Group type: EXPERIMENTAL
Intervention: PRRT with [177Lu]Lu-DOTATATE
Number of subjects: 0
Study 38581469 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular imaging with different radiopharmaceuticals (e.g., SST and FDG)
Number of subjects: 0
Study 38581480 — intervention group
Group type: EXPERIMENTAL
Intervention: Entresto (sacubitril)
Number of subjects: 0
Study 38581534 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 0
Study 38581534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study 38581534 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin and AIs (combined treatment)
Number of subjects: 0
Study 38581534 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA monitoring
Number of subjects: 0
Study 38581600 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 95
Study 38581600 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for rheumatology groups
Number of subjects: 95
Study 38581600 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to POCUS use
Number of subjects: 95
Study 38581600 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS infrastructure
Number of subjects: 95
Study 38581615 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB120 (120 mg)
Number of subjects: 461
Study 38581615 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB240 (240 mg)
Number of subjects: 461
Study 38581615 — intervention group
Group type: COMPARATOR
Intervention: PBO (Placebo)
Number of subjects: 461
Study 38581616 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab (700 mg for three doses, then 1400 mg/dose, intravenous every 4 weeks for 72 weeks)
Number of subjects: 88
Study 38581616 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 88
Study 38581616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 38581739 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin pulse (10 mg/70 kg, 3 doses, 5 days apart)
Number of subjects: 10
Study 38581739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 10
Study 38581814 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 542
Study 38581814 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 542
Study 38581842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin with basal-plus (BP) insulin regimen
Number of subjects: 76
Study 38581842 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 76
Study 38581926 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable tidal volume (6 ml/kg PBW ± 33% at 5-min intervals)
Number of subjects: 140
Study 38581926 — intervention group
Group type: COMPARATOR
Intervention: Fixed tidal volume (6 ml/kg PBW)
Number of subjects: 140
Study 38581958 — intervention group
Group type: EXPERIMENTAL
Intervention: New patient-centred care pathway
Number of subjects: 720
Study 38581958 — intervention group
Group type: COMPARATOR
Intervention: Usual oncologic care
Number of subjects: 720
Study 38582028 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground locomotor training
Number of subjects: 12
Study 38582092 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m²) in group A
Number of subjects: 356
Study 38582092 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-free treatment with trastuzumab and pertuzumab in group B
Number of subjects: 356
Study 38582271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg twice a day for 3 days, then 20 mg once a day for 28 days)
Number of subjects: 194
Study 38582271 — intervention group
Group type: COMPARATOR
Intervention: High-dose PPI (pantoprazole intravenous infusion 8 mg/h for 3 days, then omeprazole 20 mg twice a day for 28 days)
Number of subjects: 194
Study 38582271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Number of subjects: 194
Study 38582538 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments, structural and functional MRI, and electroencephalography in patients with UFS
Number of subjects: 200
Study 38582538 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200
Study 38582538 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UFS
Number of subjects: 200
Study 38582538 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal machine-learning model
Number of subjects: 200
Study 38582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus chemotherapy
Number of subjects: 0
Study 38582540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chemotherapy only)
Number of subjects: 0
Study 38582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study 38582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario and exploratory analyses
Number of subjects: 0
Study 38582650 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone (300 mg bid + 1000 mg od)
Number of subjects: 126
Study 38582650 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone (placebo + 1000 mg od)
Number of subjects: 126
Study 38582713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab (L + P)
Number of subjects: 253
Study 38582713 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 253
Study 38582758 — intervention group
Group type: EXPERIMENTAL
Intervention: hEDS patients
Number of subjects: 19
Study 38582758 — intervention group
Group type: EXPERIMENTAL
Intervention: hEDS patients during cognitive task
Number of subjects: 19
Study 38582758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 38582863 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Number of subjects: 45
Study 38582863 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 45
Study 38582863 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 45
Study 38582874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (modulating frequency of 2-125 Hz, maximal tolerable intensity for 30 min)
Number of subjects: 34
Study 38582874 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (current delivered for 45 s, ramping to 0 in the last 15 s)
Number of subjects: 34
Study 38582874 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 34
Study 38582874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 34
Study 38582934 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization (20 min, twice daily during the first week in ICU)
Number of subjects: 29
Study 38582934 — intervention group
Group type: COMPARATOR
Intervention: Conventional mobilization (retrospective control group)
Number of subjects: 29
Study 38582934 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization
Number of subjects: 29
Study 38582934 — intervention group
Group type: COMPARATOR
Intervention: Conventional mobilization
Number of subjects: 29
Study 38582974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-temperature cryoablation
Number of subjects: 64
Study 38583084 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally designed gamification
Number of subjects: 1062
Study 38583084 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed financial incentives
Number of subjects: 1062
Study 38583084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification + financial incentives
Number of subjects: 1062
Study 38583084 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1062
Study 38583086 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG guided by CCTA
Number of subjects: 114
Study 38583091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine
Number of subjects: 5260
Study 38583091 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent inactivated influenza vaccine
Number of subjects: 5260
Study 38583092 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran (10, 25, or 50 mg)
Number of subjects: 226
Study 38583092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 38583146 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP1-RA
Number of subjects: 200
Study 38583146 — intervention group
Group type: COMPARATOR
Intervention: Education-First (2 months of virtual education followed by medication prescription)
Number of subjects: 200
Study 38583147 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine PRO assessment (KCCQ-12 completed at each visit, results shared with clinician)
Number of subjects: 1248
Study 38583147 — intervention group
Group type: COMPARATOR
Intervention: Usual care (KCCQ-12 completed at randomization and 1 year later, not shared with clinician)
Number of subjects: 1248
Study 38583174 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Slow Flow (CSF) present in 23 participants (22.1%)
Number of subjects: 104
Study 38583174 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive coronary function testing measuring CFR and IMR
Number of subjects: 104
Study 38583174 — intervention group
Group type: COMPARATOR
Intervention: Invasive diagnosis of CMD
Number of subjects: 104
Study 38583185 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based telehealth model for guideline-directed medical therapy initiation and titration.
Number of subjects: 103
Study 38583185 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 103
Study 38583289 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously every 4 weeks
Number of subjects: 41
Study 38583289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 38583289 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 41
Study 38583316 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hormonal pessary applied once daily for the first 7 days and twice a week for the subsequent 31 days
Number of subjects: 79
Study 38583316 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hormonal pessary
Number of subjects: 79
Study 38583450 — intervention group
Group type: COMPARATOR
Intervention: Stable-dose conventional synthetic DMARDs (n=80)
Number of subjects: 160
Study 38583450 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose conventional synthetic DMARDs (n=42)
Number of subjects: 160
Study 38583450 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose conventional synthetic DMARDs tapering to withdrawal (n=38)
Number of subjects: 160
Study 38583455 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission induction with high-dose cytarabine (3 g/m²)
Number of subjects: 281
Study 38583455 — intervention group
Group type: COMPARATOR
Intervention: Disease control (watchful waiting before allogeneic HSCT)
Number of subjects: 281
Study 38583461 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive vouchers for attending motivational interviewing sessions and timely appointments at government ART clinics; equivalent to 14 days' wages over 12 months.
Number of subjects: 2314
Study 38583461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2314
Study 38583491 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 (200 mg subcutaneously every 4 weeks) + JNJ-6379 (250 mg oral daily) + NA (oral daily)
Number of subjects: 130
Study 38583491 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 + JNJ-6379 + NA
Number of subjects: 130
Study 38583491 — intervention group
Group type: COMPARATOR
Intervention: Placebo for JNJ-3989 and JNJ-6379 + active NA
Number of subjects: 130
Study 38583540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg/day for 4 weeks starting on the third day after RFA)
Number of subjects: 48
Study 38583540 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control, RFA without oral steroids)
Number of subjects: 48
Study 38583574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant-RT
Number of subjects: 1396
Study 38583574 — intervention group
Group type: COMPARATOR
Intervention: Salvage-RT
Number of subjects: 1396
Study 38583715 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled analgesia (paracetamol 1 g + ibuprofen 400 mg every 6 hours for the first 24 hours postpartum)
Number of subjects: 200
Study 38583715 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled analgesia
Number of subjects: 200
Study 38583715 — intervention group
Group type: COMPARATOR
Intervention: On-demand analgesia
Number of subjects: 200
Study 38583720 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy and local treatment of metastases
Number of subjects: 51
Study 38583720 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy after radiotherapy
Number of subjects: 51
Study 38583720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single organ metastasis
Number of subjects: 51
Study 38583802 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 142
Study 38583802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 38584058 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 + FMP1/AS02 (same site)
Number of subjects: 60
Study 38584058 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 + FMP1/AS02 (separate sites)
Number of subjects: 60
Study 38584058 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 alone
Number of subjects: 60
Study 38584058 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S-containing regimen
Number of subjects: 60
Study 38584058 — intervention group
Group type: EXPERIMENTAL
Intervention: FMP1/AS02 alone
Number of subjects: 60
Study 38584058 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 + FMP1/AS02
Number of subjects: 60
Study 38584058 — intervention group
Group type: COMPARATOR
Intervention: FMP1/AS02
Number of subjects: 60
Study 38584159 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadpill (candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg)
Number of subjects: 62
Study 38584159 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 8 mg
Number of subjects: 62
Study 38584166 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized therapeutic cancer vaccine (PTCV) GNOS-PV02 coadministered with plasmid-encoded interleukin-12 plus pembrolizumab
Number of subjects: 36
Study 38584200 — intervention group
Group type: EXPERIMENTAL
Intervention: MAKASI intervention
Number of subjects: 821
Study 38584244 — intervention group
Group type: EXPERIMENTAL
Intervention: PDDD (posterior dynamic distraction device)
Number of subjects: 7
Study 38584244 — intervention group
Group type: EXPERIMENTAL
Intervention: PDDD
Number of subjects: 7
Study 38584394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia ablation (VTA)
Number of subjects: 211
Study 38584600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuke Qianjin capsule, dosage and duration not available
Number of subjects: 0
Study 38584600 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 38584921 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiRehab platform (personalized training)
Number of subjects: 50
Study 38585154 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence as a Medical Device (AIaMD)
Number of subjects: 622
Study 38585154 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 622
Study 38585206 — intervention group
Group type: EXPERIMENTAL
Intervention: TAR-200 treatment (two 7-day or two 21-day dosing cycles)
Number of subjects: 12
Study 38585206 — intervention group
Group type: EXPERIMENTAL
Intervention: TAR-200 treatment
Number of subjects: 12
Study 38585593 — intervention group
Group type: EXPERIMENTAL
Intervention: MV140 (3 months)
Number of subjects: 0
Study 38585593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 months)
Number of subjects: 0
Study 38585592 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) for renal tumors
Number of subjects: 8566
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use during pregnancy
Number of subjects: 254
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 254
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing instability
Number of subjects: 254
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more adverse childhood experiences
Number of subjects: 254
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical or emotional abuse during pregnancy
Number of subjects: 254
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity during pregnancy
Number of subjects: 254
Study 38585728 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity during pregnancy (after controlling for demographic characteristics)
Number of subjects: 254
Study 38585865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 12 months
Number of subjects: 62